Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose DA, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, June CH. Sci Transl Med. 2015 Sep 02;7(303):303ra139 | doi: 10.1126/scitranslmed.aac5415
Summary
A Science Translational Medicine report details the mature results from the initial CAR T cell trial for Chronic Lymphocytic Leukemia (CLL) at Penn. For eight of 14 patients, CAR T cell persistence correlated with clinical responses, with some complete remissions continuing past four and a half years. No patient with CLL who achieved complete remission relapsed, and no minimal residual disease was detected.
Read the Department of Communications news release.
